Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells.

Cancer research - 1 Nov 2010

Gopal Y N Vashisht, Deng Wanleng, Woodman Scott E, Komurov Kakajan, Ram Prahlad, Smith Paul D, Davies Michael A

Abstract excerpt

The majority of melanomas show constitutive activation of the RAS-RAF-MAP/ERK kinase (MEK)-mitogen-activated protein kinase (MAPK) pathway. AZD6244 is a selective MEK1/2 inhibitor that markedly reduces tumor P-MAPK levels, but it produces few clinical responses in melanoma patients. An improved understanding of the determinants of resistance to AZD6244 may lead to improved patient selection and effective...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzimidazoles
Share to Extracellular Signal-Regulated MAP Kinases

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Phosphatidylinositol 3-Kinase

Share to Phosphoinositide-3 Kinase Inhibitors

Share to Proto-Oncogene Proteins c-akt

Share to PTEN Phosphohydrolase

Share to RNA, Small Interfering

Share to Skin Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 20959481
DOI: 10.1158/0008-5472.CAN-10-0902
PMCID: PMC4286702

Genes

PTEN

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells.PMID 20959481Read ↗

High level of AKT activity is associated with resistance to MEK inhibitor AZD6244 (ARRY-142886).Semantic proximity Read ↗

Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanomaSemantic proximity Read ↗

AXL/AKT axis mediated-resistance to BRAF inhibitor depends on PTEN status in melanoma.Semantic proximity Read ↗

Comparative analysis of MAPK and PI3K/AKT pathway activation and inhibition in human and canine melanoma.Semantic proximity Read ↗

PERK mediates resistance to BRAF inhibition in melanoma with impaired PTENSemantic proximity Read ↗

BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins.Semantic proximity Read ↗

The Novel ATP-Competitive MEK/Aurora Kinase Inhibitor BI-847325 Overcomes Acquired BRAF Inhibitor Resistance through Suppression of Mcl-1 and MEK Expression.Semantic proximity Read ↗

<i>BRAF</i> Gene Amplification Can Promote Acquired Resistance to MEK Inhibitors in Cancer Cells Harboring the BRAF V600E MutationSemantic proximity Read ↗

Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status.Semantic proximity Read ↗

PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression.Semantic proximity Read ↗

PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas.Semantic proximity Read ↗

NAD/NAMPT and mTOR Pathways in Melanoma: Drivers of Drug Resistance and Prospective Therapeutic TargetsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.